Compare Fox Corp Class B (FOX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Travere Therapeutics Inc. Common Stock — how do they compare? Fox Corp Class B trades at $55.56 (market cap $24.91B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Fox Corp Class B is far larger — about 5.1× Travere Therapeutics Inc. Common Stock's market cap, and Fox Corp Class B pays a 1.04% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FOX | TVTX | |
|---|---|---|
Market Cap | $24.91B | $4.88B |
Volume | 395,394 | 1,668,577 |
Sector | Media | Health |
52-Week High | $67.76 | $67.52 |
52-Week Low | $44.39 | $26.79 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $28.27B | $5.01B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.68, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 exceeding the $1.44 estimate. Fundamentals show robust revenue growth to $16.30 billion in 2025 and a net income margin of 13.88%. Analyst consensus is a Buy with a $84.75 price target, implying significant upside, though cash flow projections for 2026 indicate a potential net outflow.
The outlook for FOX is positive based on solid fundamentals and analyst optimism, but risks include a projected net cash flow deficit in 2026 and competitive pressures in the media sector. The stock presents a value opportunity with a P/E of 14.56 trading below the analyst target, yet investors should monitor execution against future earnings expectations and industry headwinds.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
